Abstract 2914
Background
Acute lymphoblastic leukaemia (ALL) is associated with high survival rates in paediatrics and young adults and less favourable outcomes in older adults. Clinical trials (CTs) studying survival-based endpoints in ALL lead to significantly prolonged trial durations, resulting in delays to medicines access. Biomarkers in ALL have been correlated with longer-term outcomes, potentially accelerating the clinical development of novel treatments. The aim of this study was to characterise efficacy measures investigated in ALL CTs conducted in the European Union (EU)/Economic Area (EEA).
Methods
Interventional Phase II to Phase IV ALL CTs registered in the EU Clinical Trials Register over an 11-year period (2007-2017) were identified. Therapeutic CTs reporting efficacy data in the English language for investigational medicinal products of chemical, biological and biotechnological origin were included in the study. A protocol design or age filter was not applied to avoid limiting the scope of outcomes identified. Primary and secondary efficacy endpoints were extracted from the selected CTs and categorised according to type of measurement. A data mining process was performed to detect trends in outcomes studied.
Results
The data set comprised 68 CTs representing about 20,000 patients. The majority of trials (69%, n = 47) recruited patients from the adult population (18-64 years) and conducted only Phase II studies (62%, n = 42). Twenty-three unique efficacy endpoints were identified and stratified into the clusters of survival (n = 4), time-to-event (n = 3), response rates and biomarkers (n = 11) and other (n = 5). Fifty-three per cent (n = 36) of the trials reported 4-10 outcomes, with a mean of 4 outcomes per CT (range 1-10). The principal endpoints evaluated in CTs consisted of overall survival (CTs: 63%, n = 43), minimal residual disease (CTs: 50%, n = 34), event-free survival (CTs: 40%, n = 27) and disease-free survival (CTs: 40%, n = 27).
Conclusions
The high uptake of minimal residual disease as an efficacy parameter in ALL CTs is in line with reported findings confirming the prognostic value of this marker on clinical outcomes. Heterogeneity in the selection of efficacy endpoints was observed which warrants future work on the standardisation of efficacy outcomes in ALL CTs.
Clinical trial identification
Editorial acknowledgement
The Malta Medicines Authority. The Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta.
Legal entity responsible for the study
Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta.
Funding
Government of Malta, Endeavour Scholarship Scheme 2017.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3157 - Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203)
Presenter: Yihebali Chi
Session: Poster Display session 1
Resources:
Abstract
3710 - The effect of treatment line on the efficacy of Anlotinib hydrochloride in advanced alveolar soft part sarcoma patients
Presenter: Zhiwei Fang
Session: Poster Display session 1
Resources:
Abstract
3184 - Prior exposure to pazopanib (PAZ) did not minor efficacy of regorafenib (REG) in non-adipocytic soft tissue sarcoma patients (pts)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
798 - Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumor (TGCT): characterization of hepatic adverse reactions (ARs)
Presenter: Sebastian Bauer
Session: Poster Display session 1
Resources:
Abstract
6117 - VEGFR2 and ITGA polymorphisms as novel pan-sarcoma biomarkers for sensitivity prediction as well as toxicity prevention anti-angiogenesis therapy in pediatric and young adult
Presenter: Qiyuan Bao
Session: Poster Display session 1
Resources:
Abstract
5450 - Reversion of resistance to mTOR inhibitors with the addition of exemestane in patients with malignant PEComa.
Presenter: Roberta Sanfilippo
Session: Poster Display session 1
Resources:
Abstract
4279 - Efficacy and Safety of VEGFR2 Inhibitor Apatinib combined with chemotherapy for Sarcoma in Stage IV
Presenter: Zhiwu Ren
Session: Poster Display session 1
Resources:
Abstract
5929 - Outcomes of metastatic soft tissue sarcoma treated with Pazopanib from dedicated medical oncology sarcoma clinic: A holistic care approach from a developing country
Presenter: Akhil Kapoor
Session: Poster Display session 1
Resources:
Abstract
2469 - Inhibition of mTOR signaling enhances Trabectedin activity in Soft Tissue Sarcoma
Presenter: David Moura
Session: Poster Display session 1
Resources:
Abstract
4210 - Efficacy and safety of apatinib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial
Presenter: Zhaolun Cai
Session: Poster Display session 1
Resources:
Abstract